WellDoc Receives $20 Million to Support BlueStar, an FDA-Approved Mobile Prescription Therapy
Summary
WellDoc secured $20 million to support BlueStar, its FDA-approved mobile prescription therapy. The funding strengthens the company’s ability to expand and sustain its digital health offering. BlueStar sits in the healthcare software space, making this news relevant to ISV and SaaS audiences focused on health tech. The update points to continued commercialization of a regulated software product in the healthcare market.
Funding
Amount
$20.0M
Total raised
Date
August 14, 2021
Announcement date
Investors
-
Lead investors
Company
welldoc.com
Funded company
Classifications
industries
HealthTech
applications
Data Management
AskAI Classifications
Labels
Digital Health
Chronic Care Management
SaaS
Linked Companies
Welldoc
$10M to $25M